Table of Contents

Post-pandemic Era-Global CINV Existing and Pipeline Drugs Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate
1 Market Scope
    1.1 Product Details and Introduction
      1.1.1 Aloxi -Product Introduction and Major Company
      1.1.2 Zofran Generic -Product Introduction and Major Company
      1.1.3 Kytril Generic -Product Introduction and Major Company
      1.1.4 Emend -Product Introduction and Major Company
      1.1.5 Akynzeo -Product Introduction and Major Company
      1.1.6 SUSTOL -Product Introduction and Major Company
      1.1.7 Rolapitant -Product Introduction and Major Company
    1.2 Market Snapshot
      1.2.1 Major Companies Overview
      1.2.2 Market Concentration
      1.2.3 Five-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
    2.1 Regional Market Share in Terms of Sales (2018 & 2022 & 2026)
    2.2 Regional Market Share in Terms of Revenue (2018 & 2022 & 2026)
    2.3 Regional Market Share in Terms of Consumption (2018 & 2022 & 2026)
3 Global CINV Existing and Pipeline Drugs Market Assessment by Type
    3.1 Global CINV Existing and Pipeline Drugs Sales by Type (2018-2028)
    3.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2018-2028)
    3.3 North America CINV Existing and Pipeline Drugs Sales and Revenue by Type (2018-2028)
    3.4 Asia CINV Existing and Pipeline Drugs Sales and Revenue by Type (2018-2028)
    3.5 Europe CINV Existing and Pipeline Drugs Sales and Revenue by Type (2018-2028)
    3.6 Middle East & Africa CINV Existing and Pipeline Drugs Sales and Revenue by Type (2018-2028)
    3.7 South America CINV Existing and Pipeline Drugs Sales and Revenue by Type (2018-2028)

4 Historical & Forecast Global CINV Existing and Pipeline Drugs Market Assessment by Application
    4.1 Global CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)
    4.2 North America CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)
    4.3 Asia CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)
    4.4 Europe CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)
    4.5 Middle East & Africa CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)
    4.6 South America CINV Existing and Pipeline Drugs Consumption and Consumption in Different Application Field (2018-2028)

5 North America
    5.1 US CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    5.2 Canada CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    5.3 Mexico CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
6 Asia
    6.1 China CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    6.2 Japan CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    6.3 India CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    6.4 Korea CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    6.5 Southeat Asia CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
7 Europe
    7.1 Germany CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    7.2 UK CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    7.3 France CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    7.4 Russia CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    7.5 Italy CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
8 Middle East and Africa
    8.1 Saudi CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    8.2 UAE CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    8.3 Egypt CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    8.4 Nigeria CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    8.5 South Africa CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
9 South America
    9.1 Brazil CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    9.2 Argentina CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
    9.3 Colombia CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2028)
10 Global CINV Existing and Pipeline Drugs Average Price Trend
    10.1 Market Price for Each Type of CINV Existing and Pipeline Drugs in North America (2018-2028)
    10.2 Market Price for Each Type of CINV Existing and Pipeline Drugs in Asia (2018-2028)
    10.3 Market Price for Each Type of CINV Existing and Pipeline Drugs in Europe (2018-2028)
    10.4 Market Price for Each Type of CINV Existing and Pipeline Drugs in Middle East & Africa (2018-2028)
    10.5 Market Price for Each Type of CINV Existing and Pipeline Drugs in South America (2018-2028)

11 Value Chain
    11.1 CINV Existing and Pipeline Drugs Value Chain Analysis
      11.1.1 Upstream
      11.1.2 Downstream
    11.2 COVID-19 Impact on CINV Existing and Pipeline Drugs Industry
      11.2.1 Industrial Policy Issued Under the Epidemic Situation
      11.2.2 Post-pandemic Era
    11.3 Cost-Under the Epidemic Situation
      11.3.1 Cost of Raw Material
    11.4 Channel Analysis
      11.4.1 Distribution Channel-Under the Epidemic Situation
      11.4.2 Distributors

12 Major Players of Global CINV Existing and Pipeline Drugs Market, Competitive Analysis
     12.1 GlaxoSmithKline
        12.1.1 GlaxoSmithKline Company Profiles and Company News
        12.1.2 GlaxoSmithKline Product Introduction
        12.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue (2018-2022)
        12.1.4 SWOT Analysis
     12.2 Helsinn
        12.2.1 Helsinn Company Profiles and Company News
        12.2.2 Helsinn Product Introduction
        12.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue (2018-2022)
        12.2.4 SWOT Analysis
     12.3 Heron Therapeutics
        12.3.1 Heron Therapeutics Company Profiles and Company News
        12.3.2 Heron Therapeutics Product Introduction
        12.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue (2018-2022)
        12.3.4 SWOT Analysis
     12.4 Merck
        12.4.1 Merck Company Profiles and Company News
        12.4.2 Merck Product Introduction
        12.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue (2018-2022)
        12.4.4 SWOT Analysis
        12.5.1 Tesaro Company Profiles and Company News
        12.5.2 Tesaro Product Introduction
        12.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue (2018-2022)
        12.5.4 SWOT Analysis
13 Global CINV Existing and Pipeline Drugs Market, Competitive Landscape and Market Forecast 
    13.1 Key Companies Dominating the Global CINV Existing and Pipeline Drugs Market
    13.2 Concentration Ratio (CR5) of Global CINV Existing and Pipeline Drugs Market (2018)
       13.2.1 Market Share of Top 5 Players in Term of Revenue (2018)
    13.3 Concentration Ratio (CR5) of Global CINV Existing and Pipeline Drugs Market (2022)
       13.3.1 Market Share of Top 5 Players in Term of Revenue (2022)
14 Conclusion
15 Methodology and Data Source



List of Tables and Figures

    Figure Product Introduction
    Table Sales (K Units) and Revenue (Million USD) of Major Players (2018-2022)
    Figure Global CINV Existing and Pipeline Drugs Sales Market Share of Top 5 Players
    Table CAGR of Major Market (2021-2026)
    Table CAGR in Terms of Sales of Each Type (2018-2028)
    Table Regional Market Share in Terms of Sales (2019-2026)
    Figure Regional Market Share in Terms of Sales (2019 - 2020)
    Table Regional Market Share in Terms of Revenue (2019-2026)
    Figure Regional Market Share in Terms of Revenue (2019 - 2020)
    Figure Regional Market Share in Terms of Consumption (2019 - 2020)
    Figure Regional Market Share in Terms of Consumption (2019 - 2020)
    Table Global CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure Global CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure Global CINV Existing and Pipeline Drugs Sales Market Share (%) by Type (2019 -2020)
    Table Global CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure Global CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Figure Global CINV Existing and Pipeline Drugs Revenue Market Share (%) by Type (2019-2020)
    Figure North America CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure North America CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure North America CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure North America CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Figure Asia CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure Asia CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure Asia CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure Asia CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Figure Europe CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure Europe CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure Europe CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure Europe CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Figure South America CINV Existing and Pipeline Drugs Sales (K Unit) by Type (2018-2028)
    Figure South America CINV Existing and Pipeline Drugs Sales (K Unit) and Growth Rate (2018-2028)
    Figure South America CINV Existing and Pipeline Drugs Revenue (Million USD) by Type (2018-2028)
    Figure South America CINV Existing and Pipeline Drugs Revenue (Million USD) and Growth Rate (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure Consumption (K Unit) and Growth Rate (2018-2028)
    Figure Different Application Field Consumption Market Share (%) (2019-2020)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure North America CINV Existing and Pipeline Drugs Consumption (K Unit) and Growth Rate (2018-2028)
    Figure North America CINV Existing and Pipeline Drugs Consumption Market Share (%) by Application (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure Asia CINV Existing and Pipeline Drugs Consumption (K Unit) and Growth Rate (2018-2028)
    Figure Asia CINV Existing and Pipeline Drugs Consumption Market Share (%) by Application (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure Europe CINV Existing and Pipeline Drugs Consumption (K Unit) and Growth Rate (2018-2028)
    Figure Europe CINV Existing and Pipeline Drugs Consumption Market Share (%) by Application (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Consumption (K Unit) and Growth Rate (2018-2028)
    Figure Middle East & Africa CINV Existing and Pipeline Drugs Consumption Market Share (%) by Application (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Figure South America CINV Existing and Pipeline Drugs Consumption (K Unit) and Growth Rate (2018-2028)
    Figure South America CINV Existing and Pipeline Drugs Consumption Market Share (%) by Application (2018-2028)
    Table Historical & Forecast CINV Existing and Pipeline Drugs Different Application Field Consumption (K Unit)
    Table US CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Canada CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Mexico CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table China CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Japan CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table India CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Korea CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Southeast Asia CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Germany CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table UK CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table France CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Russia CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Italy CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Saudi CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table UAE CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Egypt CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Nigeria CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table South Africa CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Brazil CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Argentina CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Colombia CINV Existing and Pipeline Drugs Capacity (K Units), Sales (K Units) and Consumption (K Units) (2018-2028) and Proportion of Products Sold
    Figure Proportion of Products Sold (%) (2015 -2026)
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in China
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in EU
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in USA
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in Japan
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in India
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in Southeast Asia
    Table Market Price (USD/Unit) for Each Type of CINV Existing and Pipeline Drugs in South America
    Figure Value Chain Structure of CINV Existing and Pipeline Drugs
    Table Value Chain
    Table Key Suppliers of Raw Material/Components
    Table Key Downstream Customer in Each Application Field
    Table Industry News List of CINV Existing and Pipeline Drugs
    Figure Cost Structure of CINV Existing and Pipeline Drugs in 2020
    Table Distributors/Traders List
    Table GlaxoSmithKline Profiles
    Table GlaxoSmithKline CINV Existing and Pipeline Drugs Product Introduction
    Figure GlaxoSmithKline CINV Existing and Pipeline Drugs Capacity (Unit), Sales (Unit), Revenue (Million USD) (2018-2022)
    Figure GlaxoSmithKline SWOT Analysis
    Table Helsinn Profiles
    Table Helsinn CINV Existing and Pipeline Drugs Product Introduction
    Figure Helsinn CINV Existing and Pipeline Drugs Capacity (Unit), Sales (Unit), Revenue (Million USD) (2018-2022)
    Figure Helsinn SWOT Analysis
    Table Heron Therapeutics Profiles
    Table Heron Therapeutics CINV Existing and Pipeline Drugs Product Introduction
    Figure Heron Therapeutics CINV Existing and Pipeline Drugs Capacity (Unit), Sales (Unit), Revenue (Million USD) (2018-2022)
    Figure Heron Therapeutics SWOT Analysis
    Table Merck Profiles
    Table Merck CINV Existing and Pipeline Drugs Product Introduction
    Figure Merck CINV Existing and Pipeline Drugs Capacity (Unit), Sales (Unit), Revenue (Million USD) (2018-2022)
    Figure Merck SWOT Analysis
    Table Tesaro Profiles
    Table Tesaro CINV Existing and Pipeline Drugs Product Introduction
    Figure Tesaro Pharma & Healthcare Capacity (Unit), Sales (Unit), Revenue (Million USD) (2018-2022)
    Figure Tesaro SWOT Analysis